Literature DB >> 12390049

Does the angiotensin II receptor antagonist losartan improve cognitive function?

Michele A Tedesco1, Gennaro Ratti, Giovanni Di Salvo, Francesco Natale.   

Abstract

Newer classes of antihypertensive agents, such as angiotensin II receptor antagonists, may offer benefits to patients in addition to their ability to lower blood pressure. It is accepted that chronic hypertension contributes to the development of cerebrovascular and cardiovascular disease, and several studies have demonstrated a link between hypertension and reduced cognitive function, especially in patients not receiving antihypertensive medication. In an initial clinical trial, the angiotensin II receptor antagonist losartan was shown to improve cognitive function in patients with hypertension, including in those who were elderly (up to 73 years of age). This effect cannot be explained by a reduction in blood pressure alone and is likely to involve interactions with the diverse biological actions of the renin-angiotensin system. Improving or maintaining cognitive function in patients with hypertension may translate into economic benefits beyond those expected due to blood pressure control, and would result in considerable quality-of-life benefits for the aging population.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390049     DOI: 10.2165/00002512-200219100-00001

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  35 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  15-year longitudinal study of blood pressure and dementia.

Authors:  I Skoog; B Lernfelt; S Landahl; B Palmertz; L A Andreasson; L Nilsson; G Persson; A Odén; A Svanborg
Journal:  Lancet       Date:  1996-04-27       Impact factor: 79.321

Review 3.  Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions.

Authors:  J W Wright; J W Harding
Journal:  Regul Pept       Date:  1995-11-10

4.  Cerebrovascular consequences of hypertension.

Authors:  S Strandgaard; O B Paulson
Journal:  Lancet       Date:  1994-08-20       Impact factor: 79.321

5.  The association between vascular risk factor-mediating medications and cognition and dementia diagnosis in a community-based sample of African-Americans.

Authors:  S S Richards; C L Emsley; J Roberts; M D Murray; K Hall; S Gao; H C Hendrie
Journal:  J Am Geriatr Soc       Date:  2000-09       Impact factor: 5.562

Review 6.  Vascular aspects in Alzheimer's disease.

Authors:  I Skoog
Journal:  J Neural Transm Suppl       Date:  2000

Review 7.  Angiotensin II receptor antagonists.

Authors:  M Burnier; H R Brunner
Journal:  Lancet       Date:  2000-02-19       Impact factor: 79.321

Review 8.  Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors.

Authors:  J Zhuo; I Moeller; T Jenkins; S Y Chai; A M Allen; M Ohishi; F A Mendelsohn
Journal:  J Hypertens       Date:  1998-12       Impact factor: 4.844

9.  Hypertension affects neurobehavioral functioning.

Authors:  J A Blumenthal; D J Madden; T W Pierce; W C Siegel; M Appelbaum
Journal:  Psychosom Med       Date:  1993 Jan-Feb       Impact factor: 4.312

10.  Effects of losartan on hypertension and left ventricular mass: a long-term study.

Authors:  M A Tedesco; G Ratti; D Aquino; G Limongelli; G di Salvo; S Mennella; D Galzerano; D Iarussi; A Iacono
Journal:  J Hum Hypertens       Date:  1998-08       Impact factor: 3.012

View more
  11 in total

1.  Molecular pathways: radiation-induced cognitive impairment.

Authors:  Dana Greene-Schloesser; Elizabeth Moore; Mike E Robbins
Journal:  Clin Cancer Res       Date:  2013-02-06       Impact factor: 12.531

Review 2.  Radiation-induced cognitive impairment--from bench to bedside.

Authors:  Dana Greene-Schloesser; Mike E Robbins
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

3.  Association of metabolic syndrome with arterial compliance in children and adolescents.

Authors:  Li Zhang; Jie Mi; Ming Li; Benyu Jiang
Journal:  Front Med China       Date:  2007-02

4.  The AT1 receptor antagonist, L-158,809, prevents or ameliorates fractionated whole-brain irradiation-induced cognitive impairment.

Authors:  Mike E Robbins; Valerie Payne; Ellen Tommasi; Debra I Diz; Fang-Chi Hsu; William R Brown; Kenneth T Wheeler; John Olson; Weiling Zhao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-10       Impact factor: 7.038

Review 5.  Pharmacological interventions to treat or prevent neurocognitive decline after brain radiation.

Authors:  Jessica W Rooney; Nadia N Laack
Journal:  CNS Oncol       Date:  2013-11

6.  Brain atrophy and white matter hyperintensity change in older adults and relationship to blood pressure. Brain atrophy, WMH change and blood pressure.

Authors:  Michael J Firbank; Rebecca M Wiseman; Emma J Burton; Brian K Saxby; John T O'Brien; Gary A Ford
Journal:  J Neurol       Date:  2007-04-20       Impact factor: 4.849

Review 7.  Heart Failure and Cognitive Impairment: Clinical Relevance and Therapeutic Considerations.

Authors:  Tuoyo O Mene-Afejuku; Monica Pernia; Uzoma N Ibebuogu; Shobhana Chaudhari; Savi Mushiyev; Ferdinand Visco; Gerald Pekler
Journal:  Curr Cardiol Rev       Date:  2019

8.  Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study.

Authors:  Kaycee M Sink; Xiaoyan Leng; Jeff Williamson; Stephen B Kritchevsky; Kristine Yaffe; Lewis Kuller; Sevil Yasar; Hal Atkinson; Mike Robbins; Bruce Psaty; David C Goff
Journal:  Arch Intern Med       Date:  2009-07-13

9.  Hypertension and Pathogenic hAPP Independently Induce White Matter Astrocytosis and Cognitive Impairment in the Rat.

Authors:  Alexander Levit; Sonny Cheng; Olivia Hough; Qingfan Liu; Yuksel Agca; Cansu Agca; Vladimir Hachinski; Shawn N Whitehead
Journal:  Front Aging Neurosci       Date:  2020-04-15       Impact factor: 5.750

10.  Angiotensins and Alzheimer's disease: a bench to bedside overview.

Authors:  Patrick G Kehoe
Journal:  Alzheimers Res Ther       Date:  2009-07-09       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.